Anticoagulante therapy for COVID-19 treatment and its impact on the oral cavity: a review
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Outros Autores: | , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Research, Society and Development |
Texto Completo: | https://rsdjournal.org/index.php/rsd/article/view/32195 |
Resumo: | Background: COVID-19 is an inflammatory disease caused by SARS-CoV-2, in which the patient can progress to a hypercoagulable state, requiring antithrombotic therapy. Objectives: To describe data from the literature on the use of anticoagulants as a treatment for COVID-19 positive patients and their impact on the oral cavity, the platelet antiaggregants and anticoagulants used to aid in the treatment of the Covid-positive patient, the exams and markers that help the choice of the therapy to be used, as well as observing the treatment and associating it with the risk of oral bleeding. Methodology: A bibliographic survey was carried out from 2012 to 2021 in the BvSalud research base. The keywords “Covid”, “anticoagulants” and “risk factors” and their corresponding words in English “Covid”, “anticoagulants and “risk factors” were used. Results: 128 articles were selected in BvSalud, after reading 68 articles were excluded, leaving 60 articles that met the criteria for literature review. Conclusion: Covid-19 is a pathology that acts on ACE2 receptors, triggering an inflammatory response and activating the coagulation cascade, hematological tests (D-dimer, fibrinogen, ferritin, prothrombin time, interleukin-6 and Protein-C- reactive) can be used to assess the patient's status. The decision to initiate anticoagulant or antiplatelet therapy should be made after evaluating these markers. Such therapy can exacerbate bleeding resulting from oral trauma at the time of intubation or from preexisting ulcers or ulcers acquired after ICU admission, the installation of ETT requires special care with the patient's oral hygiene, in view of the greater susceptibility to secondary infections. |
id |
UNIFEI_8d55a2c968b342dd737812e60c5f4acc |
---|---|
oai_identifier_str |
oai:ojs.pkp.sfu.ca:article/32195 |
network_acronym_str |
UNIFEI |
network_name_str |
Research, Society and Development |
repository_id_str |
|
spelling |
Anticoagulante therapy for COVID-19 treatment and its impact on the oral cavity: a reviewTerapia anticoagulante para el tratamiento del COVID-19 y su impacto en la cavidad oral: una revisiónO uso de anticoagulantes para o tratamento da COVID-19 e sua repercussão na cavidade oral: revisão de literaturaCovid-19AnticoagulantsRisk factors.Covid-19AnticoagulantesFactores de riesgo.Covid-19AnticoagulantesFatores de risco.Background: COVID-19 is an inflammatory disease caused by SARS-CoV-2, in which the patient can progress to a hypercoagulable state, requiring antithrombotic therapy. Objectives: To describe data from the literature on the use of anticoagulants as a treatment for COVID-19 positive patients and their impact on the oral cavity, the platelet antiaggregants and anticoagulants used to aid in the treatment of the Covid-positive patient, the exams and markers that help the choice of the therapy to be used, as well as observing the treatment and associating it with the risk of oral bleeding. Methodology: A bibliographic survey was carried out from 2012 to 2021 in the BvSalud research base. The keywords “Covid”, “anticoagulants” and “risk factors” and their corresponding words in English “Covid”, “anticoagulants and “risk factors” were used. Results: 128 articles were selected in BvSalud, after reading 68 articles were excluded, leaving 60 articles that met the criteria for literature review. Conclusion: Covid-19 is a pathology that acts on ACE2 receptors, triggering an inflammatory response and activating the coagulation cascade, hematological tests (D-dimer, fibrinogen, ferritin, prothrombin time, interleukin-6 and Protein-C- reactive) can be used to assess the patient's status. The decision to initiate anticoagulant or antiplatelet therapy should be made after evaluating these markers. Such therapy can exacerbate bleeding resulting from oral trauma at the time of intubation or from preexisting ulcers or ulcers acquired after ICU admission, the installation of ETT requires special care with the patient's oral hygiene, in view of the greater susceptibility to secondary infections.Fundamentos: A COVID-19 é uma doença inflamatória causó pelo SARS-CoV-2, na qual p paciente pode evoluir para um estado hipercoagulavel, necesitándose de terapia antitrombótica. Objetivos: Descrever dados da literatura sobre o uso de anticoagulantes como tratamiento para pacientes COVID-19 positivo y su repercussão na cavidade oral, os antiagregantes plaquetários e anticoagulantes utilizados para auxilio de tratamiento de pacientes COVID -positivo, os exames e marcadores que auxiliam a escolha da terapia a ser utilizada, así como observar o tratar y asociar ao riesgo de hemorragia oral. Metodología: Foi realizado um levantamiento bibliográfico no período de 2012 a 2021 na base de pesquisa BvSalud. Foram usó as palavras-chaves “ COVID ”, “anticoagulantes” e “fatores de risco” y seus correspondientes em inglês “ COVID ”, “anticoagulants e “riskfactors”. Results: Foram selecionados 128 artigos na BvSalud, após a leitura foram excluídos 68 artigos, restando 60 artigos that adentiam os critérios for revisão de literatura. Conclusión: A COVID -19 é uma patologia que age sobre os receptores ECA2, desencadeando uma resposta inflamatória e ativando a cascata de coagulação, exames hematológicos (D-dimero, fibrinogenio, ferritina, tempo de protrombina, interleucina-6 and Proteina-C- reativa) puede ser utilizado para evaluar o estado del paciente. Una decisión de iniciar una terapia anticoagulante o antiagregante deve ocorrer después de una evaluación de los marcadores. Tal terapia puede exacerbar sangramentos decorativos de traumas o no hay momento de intubação ou de úlceras preexistentes ou adquiridas después de admisión en UTI, una instalación do TET requiere cuidados especiales com a higiene oral del paciente, tendo em vista a maior susceptibilidade as infecções secundárias.Fundamentos: A COVID-19 é uma doença inflamatória causada pelo SARS-CoV-2, na qual p paciente pode evoluir para um estado hipercoagulavel, necessitando de terapia antitrombótica. Objetivos: Descrever dados da literatura sobre o uso de anticoagulantes como tratamento para pacientes COVID-19 positivo e sua repercussão na cavidade oral, os antiagregantes plaquetários e anticoagulantes utilizados para auxílio de tratamento do paciente Covid-positivo, os exames e marcadores que auxiliam a escolha da terapia a ser utilizada, assim como observar o tratamento e associar ao risco de hemorragia oral. Metodologia: Foi realizado um levantamento bibliográfico no período de 2012 a 2021 na base de pesquisa BvSalud. Foram utilizadas as palavras-chaves “Covid”, “anticoagulantes” e “fatores de risco” e seus correspondentes em inglês “Covid”, “anticoagulants e “risk factors”. Resultados: Foram selecionados 128 artigos na BvSalud, após a leitura foram excluídos 68 artigos, restando 60 artigos que atendem os critérios para revisão de literatura. Conclusão: A Covid-19 é uma patologia que age sobre os receptores ECA2, desencadeando uma resposta inflamatória e ativando a cascata de coagulação, exames hematológicos (D-dimero, fibrinogenio, ferritina, tempo de protrombina, interleucina-6 e Proteina-C-reativa) podem ser utilizados para avaliar o estado do paciente. A decisão de iniciar a terapia anticoagulante ou antiagregante deve ocorrer após a avaliação desses marcadores. Tal terapia pode exacerbar sangramentos decorrentes de traumas orais no momento de intubação ou de úlceras preexistentes ou adquiridas após admissão em UTI, a instalação do TET requer cuidados especiais com a higiene oral do paciente, tendo em vista a maior susceptibilidade as infecções secundárias.Research, Society and Development2022-07-20info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/3219510.33448/rsd-v11i9.32195Research, Society and Development; Vol. 11 No. 9; e59611932195Research, Society and Development; Vol. 11 Núm. 9; e59611932195Research, Society and Development; v. 11 n. 9; e596119321952525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/32195/27485Copyright (c) 2022 Igor Almeida de Moura Barros; Gabriela De Morais Guerra Ferraz; Ully Dias Nascimento Tavora Cavalcanti https://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessBarros, Igor Almeida de Moura Ferraz, Gabriela De Morais Guerra Cavalcanti , Ully Dias Nascimento Tavora 2022-07-21T12:36:16Zoai:ojs.pkp.sfu.ca:article/32195Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:48:16.409660Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false |
dc.title.none.fl_str_mv |
Anticoagulante therapy for COVID-19 treatment and its impact on the oral cavity: a review Terapia anticoagulante para el tratamiento del COVID-19 y su impacto en la cavidad oral: una revisión O uso de anticoagulantes para o tratamento da COVID-19 e sua repercussão na cavidade oral: revisão de literatura |
title |
Anticoagulante therapy for COVID-19 treatment and its impact on the oral cavity: a review |
spellingShingle |
Anticoagulante therapy for COVID-19 treatment and its impact on the oral cavity: a review Barros, Igor Almeida de Moura Covid-19 Anticoagulants Risk factors. Covid-19 Anticoagulantes Factores de riesgo. Covid-19 Anticoagulantes Fatores de risco. |
title_short |
Anticoagulante therapy for COVID-19 treatment and its impact on the oral cavity: a review |
title_full |
Anticoagulante therapy for COVID-19 treatment and its impact on the oral cavity: a review |
title_fullStr |
Anticoagulante therapy for COVID-19 treatment and its impact on the oral cavity: a review |
title_full_unstemmed |
Anticoagulante therapy for COVID-19 treatment and its impact on the oral cavity: a review |
title_sort |
Anticoagulante therapy for COVID-19 treatment and its impact on the oral cavity: a review |
author |
Barros, Igor Almeida de Moura |
author_facet |
Barros, Igor Almeida de Moura Ferraz, Gabriela De Morais Guerra Cavalcanti , Ully Dias Nascimento Tavora |
author_role |
author |
author2 |
Ferraz, Gabriela De Morais Guerra Cavalcanti , Ully Dias Nascimento Tavora |
author2_role |
author author |
dc.contributor.author.fl_str_mv |
Barros, Igor Almeida de Moura Ferraz, Gabriela De Morais Guerra Cavalcanti , Ully Dias Nascimento Tavora |
dc.subject.por.fl_str_mv |
Covid-19 Anticoagulants Risk factors. Covid-19 Anticoagulantes Factores de riesgo. Covid-19 Anticoagulantes Fatores de risco. |
topic |
Covid-19 Anticoagulants Risk factors. Covid-19 Anticoagulantes Factores de riesgo. Covid-19 Anticoagulantes Fatores de risco. |
description |
Background: COVID-19 is an inflammatory disease caused by SARS-CoV-2, in which the patient can progress to a hypercoagulable state, requiring antithrombotic therapy. Objectives: To describe data from the literature on the use of anticoagulants as a treatment for COVID-19 positive patients and their impact on the oral cavity, the platelet antiaggregants and anticoagulants used to aid in the treatment of the Covid-positive patient, the exams and markers that help the choice of the therapy to be used, as well as observing the treatment and associating it with the risk of oral bleeding. Methodology: A bibliographic survey was carried out from 2012 to 2021 in the BvSalud research base. The keywords “Covid”, “anticoagulants” and “risk factors” and their corresponding words in English “Covid”, “anticoagulants and “risk factors” were used. Results: 128 articles were selected in BvSalud, after reading 68 articles were excluded, leaving 60 articles that met the criteria for literature review. Conclusion: Covid-19 is a pathology that acts on ACE2 receptors, triggering an inflammatory response and activating the coagulation cascade, hematological tests (D-dimer, fibrinogen, ferritin, prothrombin time, interleukin-6 and Protein-C- reactive) can be used to assess the patient's status. The decision to initiate anticoagulant or antiplatelet therapy should be made after evaluating these markers. Such therapy can exacerbate bleeding resulting from oral trauma at the time of intubation or from preexisting ulcers or ulcers acquired after ICU admission, the installation of ETT requires special care with the patient's oral hygiene, in view of the greater susceptibility to secondary infections. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-07-20 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/32195 10.33448/rsd-v11i9.32195 |
url |
https://rsdjournal.org/index.php/rsd/article/view/32195 |
identifier_str_mv |
10.33448/rsd-v11i9.32195 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/32195/27485 |
dc.rights.driver.fl_str_mv |
https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Research, Society and Development |
publisher.none.fl_str_mv |
Research, Society and Development |
dc.source.none.fl_str_mv |
Research, Society and Development; Vol. 11 No. 9; e59611932195 Research, Society and Development; Vol. 11 Núm. 9; e59611932195 Research, Society and Development; v. 11 n. 9; e59611932195 2525-3409 reponame:Research, Society and Development instname:Universidade Federal de Itajubá (UNIFEI) instacron:UNIFEI |
instname_str |
Universidade Federal de Itajubá (UNIFEI) |
instacron_str |
UNIFEI |
institution |
UNIFEI |
reponame_str |
Research, Society and Development |
collection |
Research, Society and Development |
repository.name.fl_str_mv |
Research, Society and Development - Universidade Federal de Itajubá (UNIFEI) |
repository.mail.fl_str_mv |
rsd.articles@gmail.com |
_version_ |
1797052769158299648 |